In vivo Biodistribution and Urinary Excretion of Mesoporous Silica Nanoparticles: Effects of Particle Size and PEGylation
In vivo Biodistribution and Urinary Excretion of Mesoporous Silica Nanoparticles: Effects of Particle Size and PEGylation
复制标题
介孔二氧化硅纳米粒子的体内生物分布和尿液排泄：粒径和聚乙二醇化的影响
DOI：
10.1002/smll.201001459
复制
发表时间：
2011-01-17
期刊：
影响因子：
13.3
通讯作者：
Shi, Jianlin
中科院分区：
文献类型：
--
作者：
He, Qianjun;Zhang, Zhiwen;Shi, Jianlin
通过ICR小鼠尾静脉注射评价了球形介孔二氧化硅纳米粒子（MSNs）的体内生物分布和尿排泄，并考察了粒径和PEG化对MSNs的影响。结果表明，不同粒径（80-360 nm）的MSNs和PEG化MSNs主要分布在肝脏和脾脏中，少数分布在肺中，少数分布在肾脏和心脏中。较小粒径的PEG化MSN更容易逃脱肝、脾和肺组织的捕获，具有更长的血液循环寿命，并且生物降解更慢，相应地在尿中具有更低的降解产物排泄量。MSN和PEG化MSN在体内1个月后均不引起组织毒性。
The in vivo biodistribution and urinary excretion of spherical mesoporous silica nanoparticles (MSNs) are evaluated by tail-vein injection in ICR mice, and the effects of the particle size and PEGylation are investigated. The results indicate that both MSNs and PEGylated MSNs of different particle sizes (80-360 nm) distribute mainly in the liver and spleen, a minority of them in the lungs, and a few in the kidney and heart. The PEGylated MSNs of smaller particle size escape more easily from capture by liver, spleen, and lung tissues, possess longer blood-circulation lifetime, and are more slowly biodegraded and correspondingly have a lower excreted amount of degradation products in the urine. Neither MSNs nor PEGylated MSNs cause tissue toxicity after 1 month in vivo.